Underlying Treatment of Myeloproliferative Neoplasms

Video

Underlying Treatment of Myeloproliferative Neoplasms

January 2016

  • A 59-year-old male presents to his physician with symptoms of fatigue and abdominal pain lasting 3 months; he also reports increased bruising
    • Physical Exam: Spleen is palpable, 6 cm. below left costal margin
  • CBC with differential
    • RBC; 3.20 x 1012/L
    • HGB; 9.3 g/dL
    • HCT; 34%
    • MCV; 93.1 fL
    • WBC; 12.1 x 109/L
    • PLT; 247 x 109/L
    • PB BLASTS; 0%
  • Genetic testing showsJAK2V617Fmutation
  • Bone marrow biopsy showed megakaryocyte proliferation and atypia with evidence of reticulin fibrosis
Related Videos
Video 3 - "Managing Toxicities and Adverse Reactions in HR+/Her2-Low mBC Therapies"
Video 2 - "EMERALD: Underscoring Key Elacestrant Data + Subgroup Analyses for Informed Therapy Selection"
Video 1 - "A 62-Year-Old Woman with HR+ HER2-low Metastatic Breast Cancer and Lung, Liver, and Bone Metastases and Using Biomarker Testing to Guide Treatment Selection"
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
Related Content